Neovascular age-related macular degeneration

Ocular Disease: Mechanisms and Management

Volumn , Issue , 2010, Pages 536-543

  Lederer, David E ^a   Cousins, Scott W ^b   Csaky, Karl G ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879801478     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-2983-7.00069-3     Document Type: Chapter

References (47)

1. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity [see comment]. Arch Ophthalmol 1994, 112:480-488. Macular Photocoagulation Study Group.
2. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report [see comment] [erratum appears in Arch Ophthalmol 2000;118:488]. Arch Ophthalmol 1999, 117:1329-1345.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration [see comment]. N Engl J Med 2006, 355:1432-1444.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration [see comment]. N Engl J Med 2006, 355:1419-1431.
5. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States [see comment]. Arch Ophthalmol 2004, 122:564-572.
6. Yannuzzi LA, Wong DW, Sforzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 1999, 117:1503-1510.
7. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration [see comment]. Retina 2001, 21:416-434.
8. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001, 20:705-732.
9. Feeney-Burns L, Hilderbrand ES, Eldridge S Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci 1984, 25:195-200.
10. Hughes AE, Orr N, Patterson C, et al. Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking. PLoS Med 2007, 4:e355.
11. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 [see comment]. Arch Ophthalmol 2001, 119:1417-1436. Age-Related Eye Disease Study Research G.
12. Cousins SW, Espinosa-Heidmann DG, Csaky KG Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization. Arch Ophthalmol 2004, 122:1013-1018.
13. Killingsworth MC Angiogenesis in early choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1995, 233:313-323.
14. Csaky KG, Baffi JZ, Byrnes GA, et al. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res 2004, 78:1107-1116.
15. Espinosa-Heidmann DG, Caicedo A, Hernandez EP, et al. Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44:4914-4919.
16. Klein R, Wang Q, Klein BE, et al. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995, 36:182-191.
17. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch Ophthalmol 1998, 116:653-658.
18. Fine AM, Elman MJ, Ebert JE, et al. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986, 104:513-514.
19. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008, 115:116-126.
20. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials [see comment]. Arch Ophthalmol 1994, 112:500-509. Macular Photocoagulation Study Group.
21. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report no. 3. Arch Ophthalmol 2002, 120:1443-1454.
22. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration [see comment]. N Engl J Med 2004, 351:2805-2816.
23. Rosenfeld PJ, Moshfeghi AA, Puliafito CA Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration [see comment]. Ophthalm Surg Lasers Imag 2005, 36:331-335.
24. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006, 26:383-390.
25. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999, 293:865-881.
26. Vaclavik V, Vujosevic S, Dandekar SS, et al. Autofluorescence imaging in age-related macular degeneration complicated by choroidal neovascularization: a prospective study. Ophthalmology 2008, 115:342-346.
27. Sarks S, Cherepanoff S, Killingsworth M, et al. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci 2007, 48:968-977.
28. Spraul CW, Lang GE, Grossniklaus HE, et al. Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol 1999, 44(Suppl. 1):S10-S32.
29. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002, 8:119-126.
30. Seregard S, Algvere PV, Berglin L Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol 1994, 232:325-329.
31. Ramrattan RS, van der Schaft TL, Mooy CM, et al. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 1994, 35:2857-2864.
32. Moore DJ, Clover GM The effect of age on the macromolecular permeability of human Bruch's membrane. Invest Ophthalmol Vis Sci 2001, 42:2970-2975.
33. Hammond CJ, Webster AR, Snieder H, et al. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology 2002, 109:730-736.
34. Montezuma SR, Sobrin L, Seddon JM Review of genetics in age related macular degeneration. Semin Ophthalmol 2007, 22:229-240.
35. Tan JSL, Wang JJ, Flood V, et al. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008, 115:334-341.
36. Klein R, Klein BE, Linton KL, et al. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol 1993, 137:190-200.
37. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000, 45:115-134.
38. Marin-Castano ME, Csaky KG, Cousins SW Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. Invest Ophthalmol Vis Sci 2005, 46:3331-3340.
39. Marin-Castano ME, Striker GE, Alcazar O, et al. Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci 2006, 47:4098-4112.
40. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44:3586-3592.
41. Takahashi T, Nakamura T, Hayashi A, et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am J Ophthalmol 2000, 130:774-781.
42. Sengupta N, Caballero S, Mames RN, et al. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44:4908-4913.
43. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996, 37:855-868.
44. Campochiaro PA Retinal and choroidal neovascularization. J Cell Physiol 2000, 184:301-310.
45. Lu M, Adamis AP Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 2006, 19:323-334.
46. Luttun A, Carmeliet G, Carmeliet P Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 2002, 12:88-96.
47. Espinosa-Heidmann DG, Reinoso MA, Pina Y, et al. Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res 2005, 80:369-378.